Abstract
1. Pharmacogenomics. 2023 Jan;24(1):27-57. doi: 10.2217/pgs-2022-0137. Epub 2023 Jan 11. Pharmacogenetics of anxiety and depression in Alzheimer's disease. Cacabelos R(1), Carril JC(2), Corzo L(3), Pego R(4), Cacabelos N(5), Alcaraz M(6), Muñiz A(6), Martínez-Iglesias O(7), Naidoo V(8). Author information: (1)Department of Genomic Medicine, International Center of Neuroscience & Genomic Medicine, EuroEspes Biomedical Research Center, Bergondo, Corunna, 15165, Spain. (2)Department of Genomics & Pharmacogenomics, International Center of Neuroscience & Genomic Medicine, EuroEspes Biomedical Research Center, Bergondo, Corunna, 15165, Spain. (3)Department of Medical Biochemistry, International Center of Neuroscience & Genomic Medicine, EuroEspes Biomedical Research Center, Bergondo, Corunna, 15165, Spain. (4)Department of Neuropsychology, International Center of Neuroscience & Genomic Medicine, EuroEspes Biomedical Research Center, Bergondo, Corunna, 15165, Spain. (5)Department of Medical Documentation, International Center of Neuroscience & Genomic Medicine, EuroEspes Biomedical Research Center, Bergondo, Corunna, 15165, Spain. (6)Department of Nursing, International Center of Neuroscience & Genomic Medicine, EuroEspes Biomedical Research Center, Bergondo, Corunna, 15165, Spain. (7)Department of Medical Epigenetics, International Center of Neuroscience & Genomic Medicine, EuroEspes Biomedical Research Center, Bergondo, Corunna, 15165, Spain. (8)Department of Basic Neuroscience, International Center of Neuroscience & Genomic Medicine, EuroEspes Biomedical Research Center, Bergondo, Corunna, 15165, Spain. Anxiety and depression coexist with cognitive impairment in Alzheimer's disease along with other concomitant disorders (>60%), which require multipurpose treatments. Polypharmaceutical regimens cause drug-drug interactions and adverse drug reactions, potentially avoidable in number and severity with the implementation of pharmacogenetic procedures. The accumulation of defective variants (>30 genes per patient in more than 50% of cases) in pharmagenes (pathogenic, mechanistic, metabolic, transporter, pleiotropic) influences the therapeutic response to antidementia, antidepressant and anxiolytic drugs in polyvalent regimens. APOE, CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, CYP3A5, CYP4F2, COMT, MAOB, CHAT, GSTP1, NAT2, SLC30A8, SLCO1B1, ADRA2A, ADRB2, BCHE, GABRA1, HMGCR, HTR2C, IFNL3, NBEA, UGT1A1, ABCB1, ABCC2, ABCG2, SLC6A2, SLC6A3, SLC6A4, MTHFR and OPRM1 variants affect anxiety and depression in Alzheimer's disease. DOI: 10.2217/pgs-2022-0137 PMID: 36628952 [Indexed for MEDLINE]